Modified release formulations containing (R)-1-3-(10,11-dihydro-5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1propyl)3-piperidinecarboxylic acid

摘要

Modified release formulations with zero-order drug release containing (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid, or a pharmaceutically acceptable salt thereof, dispersed in a polymeric matrix having at least one release rate controlling polymer are useful in treating disorders related to both neurogenic inflammation and non-insulin-dependent diabetes mellitus (NIDDM).